Trial Profile
Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer Who Have Relapse in Biochemistry Whilst Androgenic Blockage
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Estramustine; Hydrocortisone; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms PROSTATA
- Sponsors Sanofi
- 08 Apr 2022 This trial has been completed (End Date: 18 Jul 2009), according to European Clinical Trials Database record.
- 29 Nov 2010 Planned end date changed from 1 Jan 2010 to 1 Jul 2009 as reported by ClinicalTrials.gov.
- 29 Nov 2010 Actual patient number is 54 as reported by ClinicalTrials.gov.